An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510951-36-00

Acronym

PSP002

Enrollment

Registered

2024-06-25

Start date

2020-11-16

Completion date

Unknown

Last updated

2025-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive Supranuclear Palsy

Brief summary

Incidence of treatment emergent adverse events from Baseline of the open-label extension to the end of the study

Interventions

DRUGBepranemab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of treatment emergent adverse events from Baseline of the open-label extension to the end of the study	—

Countries

Belgium, Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026